Skip to content
MarketScale
‹ Back to IndustriesSciences

Who Will be the Winners of Aerospace This Year?

There is a lot happening—and a lot getting ready to happen—in aerospace right now. Just last year, we saw five significant achievements in aerospace—but the two that will likely continue to be important in 2019 are AI-drive “generative design” and industrial 3-D printing. Artificial intelligence (AI) is likely going to continue to be a major…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Troy Camplin · 3d PrintingAerospaceBezosBranson
Share
Who Will be the Winners of Aerospace This Year?

Key takeaways

01

There is a lot happening—and a lot getting ready to happen—in aerospace right now.

02

Just last year, we saw five significant achievements in aerospace—but the two that will likely continue to be important in 2019 are AI-drive “generative design” and industrial 3-D printing.

03

Artificial intelligence (AI) is likely going to continue to be a major…

There is a lot happening—and a lot getting ready to happen—in aerospace right now. Just last year, we saw five significant achievements in aerospace—but the two that will likely continue to be important in 2019 are AI-drive “generative design” and industrial 3-D printing.

Artificial intelligence (AI) is likely going to continue to be a major driver in a large number of industries, including all areas of design, and especially in aerospace design. Stronger yet lighter designs are the key to aerospace, and there is nothing that can drive both of these trends simultaneously like generative design. It is likely this will become especially important as the “space” part of “aerospace” moves more to the forefront.

Industrial 3-D printing will allow engineers to produce many of the parts designed through generative design—as well, of course, from standard design practices. This will save a great deal of time while also reducing waste. It will also allow for a great deal of manufacturing in space—it would certainly be more space-efficient to pack up printing materials and then print structures on site.

On Oct. 24, 2003, the Concorde landed for the very last time—ending supersonic passenger service. Yet, in 2019, Denver-based startup ‘Boom’ is planning to test-fly its own supersonic passenger jet, Overture. The fact that it has raised $100 million to bring its total funding to $141 million is certainly a sign that there are those who believe in its goal of making trans-Atlantic day trips—and flights from Los Angeles to Sydney, Australia in under seven hours—a possibility. While Boom is aiming for 2020 to get commercial flights underway, perhaps the 2019 test flights will get people thinking about bigger possibilities.

Among those bigger possibilities is the real possibility of the first commercial space trip in 2019. This is Richard Branson’s goal, and the successful flight of Virgin’s SpaceShipTwo right into the edge of space is what makes it truly possible. Jeff Bezos also plans to try to send someone into space in 2019 with his Blue Origin.

Indeed, the billionaire space race is likely to continue to mark milestone after milestone. It has already resulted in technological innovations not yet achieved by the military aerospace industry with SpaceX’s rocket re-landing, and the technological innovations are likely to continue throughout the next year.

Each of these elements will likely be able to feed into the others, driving even more innovation. Space planes need supersonic technology as much as does Boom’s Overture, and supersonic planes and space planes will need stronger, lighter components made possible by generative design and 3-D printing. Lighter, stronger, faster, cheaper—these are all results of the aerospace trends in 2019.

For the latest news, videos, and podcasts in the Science Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – twitter.com/ScienceMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

About the author

TC
Troy Camplin

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

TC
Troy Camplin

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512